The second annual meeting of the European OA-BIO consortium

On the 16th and 17th of February, we organized the second annual meeting of the European OA-BIO consortium in Davos, Switzerland. 

Together with our OA-BIO partners Universiteit Utrecht, Chondrometrics GmbH, AO Research Institute Davos (ARI), and AO Foundation, we shared and discussed ongoing research on 4P004 (intra-articular liraglutide) as a potential disease-modifying osteoarthritis drug (DMOAD). 

Discussions focused on the development of novel biomarkers and the ongoing phase 1 clinical trial.